Status:
UNKNOWN
Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19
Lead Sponsor:
Fasa University of Medical Sciences
Conditions:
COVID-19
Eligibility:
All Genders
15-100 years
Phase:
PHASE2
PHASE3
Brief Summary
New Corona virus (COVID-19) has made a horrible situation for all of the countries. This disease is not only a health problem but also economy, culture and the whole entity of the countries is under a...
Detailed Description
Looking at the pathology of this disease shows that COVID-19 virus binds to the Angiotensin converting enzyme II (ACE II) which is located on the surface of different cells in the body and specially o...
Eligibility Criteria
Inclusion
- Definitely positive COVID-19 patients
Exclusion
- Patients with acute respiratory problems including patients with:
- Spo2\<60%
- Severe respiratory distress
- Heamodynamic instabilitty
- Acid base disturbance
- Severe Anemia Patients with severe hepatic diseases Patients with Nurvous system diseases
Key Trial Info
Start Date :
April 4 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 20 2020
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04331470
Start Date
April 4 2020
End Date
May 20 2020
Last Update
April 13 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vali-Asr Hospital
Fasa, Fars, Iran